See more : Mirae Asset Securities Co. Ltd. (006805.KS) Income Statement Analysis – Financial Results
Complete financial analysis of ALTEOGEN Inc. (196170.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ALTEOGEN Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Rivalry Corp. (RVLCF) Income Statement Analysis – Financial Results
- Tailwind International Acquisition Corp. (TWNIF) Income Statement Analysis – Financial Results
- Commercial International Bank (Egypt) S.A.E (CIBEY) Income Statement Analysis – Financial Results
- Yang Guang Co.,Ltd. (000608.SZ) Income Statement Analysis – Financial Results
- Adit EdTech Acquisition Corp. (ADEX) Income Statement Analysis – Financial Results
ALTEOGEN Inc. (196170.KQ)
About ALTEOGEN Inc.
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; and ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology. The company has a strategic alliance with Kissei Pharmaceutical to develop Aflibercept that has completed pre-clinical trial; and Cristalia for the development of Trastuzumab, which is in the Phase II clinical trial for the treatment of breast cancer. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 96.52B | 28.81B | 38.75B | 42.43B | 29.23B | 13.70B | 12.10B | 6.84B | 4.73B | 7.04B | 5.53B | 3.96B |
| Cost of Revenue | 65.32B | 19.40B | 24.13B | 15.38B | 18.40B | 11.86B | 11.16B | 6.28B | 213.82M | 3.17B | 1.75B | 541.69M |
| Gross Profit | 31.20B | 9.41B | 14.61B | 27.05B | 10.83B | 1.84B | 945.05M | 567.00M | 4.51B | 3.88B | 3.78B | 3.42B |
| Gross Profit Ratio | 32.32% | 32.67% | 37.71% | 63.75% | 37.06% | 13.44% | 7.81% | 8.28% | 95.48% | 55.03% | 68.31% | 86.32% |
| Research & Development | 25.31B | 26.61B | 19.39B | 16.35B | 6.46B | 5.96B | 4.65B | 3.98B | 3.03B | 1.84B | 1.04B | 731.42M |
| General & Administrative | 3.03B | 3.56B | 4.04B | 4.47B | 216.86M | 68.77M | 46.44M | 39.07M | 41.26M | 984.39M | 41.23M | 35.86M |
| Selling & Marketing | 1.99B | 1.85B | 1.50B | 1.71B | 1.04B | 487.40M | 472.75M | 414.58M | 241.59M | 300.80M | 198.81M | 295.28M |
| SG&A | 5.02B | 12.18B | 10.41B | 10.76B | 6.63B | 3.54B | 2.46B | 2.00B | 1.36B | 1.29B | 1.16B | 971.80M |
| Other Expenses | 10.61B | -747.80K | 4.00B | -14.34B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 40.94B | 38.78B | 29.80B | 27.10B | 13.08B | 9.50B | 7.12B | 5.98B | 4.39B | 3.25B | 2.20B | 1.97B |
| Cost & Expenses | 106.26B | 58.18B | 53.94B | 42.48B | 31.48B | 21.36B | 18.28B | 12.25B | 4.60B | 6.42B | 3.95B | 2.51B |
| Interest Income | 5.19B | 3.87B | 2.07B | 901.41M | 914.38M | 817.83M | 519.99M | 581.10M | 642.49M | 147.06M | 34.03M | 1.10M |
| Interest Expense | 670.88M | 425.48M | 604.66M | 796.78M | 189.61M | 0.00 | 0.00 | 0.00 | 0.00 | 97.68M | 117.93M | 0.00 |
| Depreciation & Amortization | 3.33B | 2.65B | 2.15B | 1.87B | 929.59M | 553.30M | 423.07M | 352.18M | 213.82M | 166.30M | 126.75M | 32.51M |
| EBITDA | 440.04M | -6.89B | -7.94B | -15.03B | -561.50M | -5.46B | -6.95B | -4.10B | 337.87M | 890.51M | 1.64B | 1.69B |
| EBITDA Ratio | 0.46% | -92.76% | -33.66% | 4.27% | -4.52% | -51.86% | -47.51% | -73.92% | 7.15% | 12.64% | 29.63% | 42.75% |
| Operating Income | -9.74B | -29.37B | -15.19B | -58.17M | -2.25B | -7.66B | -6.17B | -5.41B | 124.04M | 724.20M | 1.51B | 1.66B |
| Operating Income Ratio | -10.09% | -101.97% | -39.21% | -0.14% | -7.70% | -55.90% | -51.00% | -79.07% | 2.62% | 10.28% | 27.33% | 41.92% |
| Total Other Income/Expenses | 6.17B | 19.40B | 4.50B | -17.63B | 571.33M | 1.63B | -1.20B | 955.03M | 922.56M | 16.29M | 38.40M | -211.97M |
| Income Before Tax | -3.56B | -9.97B | -10.69B | -17.69B | -1.68B | -6.03B | -7.37B | -4.46B | 1.05B | 770.25M | 1.61B | 1.45B |
| Income Before Tax Ratio | -3.69% | -34.61% | -27.60% | -41.70% | -5.75% | -44.03% | -60.91% | -65.11% | 22.14% | 10.94% | 29.16% | 36.57% |
| Income Tax Expense | 17.83M | 108.05M | 893.17M | 583.06M | 57.57M | 1.04B | 76.74M | -868.96M | -161.77M | 160.90M | 5.63M | 14.35M |
| Net Income | -3.37B | -8.15B | -6.27B | -15.82B | -704.51M | -6.87B | -7.45B | -3.59B | 1.21B | 931.14M | 1.61B | 1.43B |
| Net Income Ratio | -3.49% | -28.28% | -16.20% | -37.29% | -2.41% | -50.15% | -61.54% | -52.42% | 25.57% | 13.22% | 29.06% | 36.21% |
| EPS | -65.27 | -158.85 | -103.31 | -209.53 | -14.62 | -151.13 | -165.81 | -82.74 | 28.59 | 29.58 | 84.03 | 202.92 |
| EPS Diluted | -65.27 | -158.85 | -103.31 | -209.53 | -14.62 | -151.13 | -165.81 | -79.98 | 27.53 | 29.58 | 84.03 | 202.92 |
| Weighted Avg Shares Out | 51.66M | 51.28M | 60.74M | 75.51M | 48.19M | 45.47M | 44.92M | 43.36M | 42.26M | 31.48M | 19.11M | 7.07M |
| Weighted Avg Shares Out (Dil) | 51.66M | 51.28M | 60.74M | 75.51M | 48.19M | 45.47M | 44.92M | 44.85M | 43.89M | 31.48M | 19.11M | 7.07M |
Source: https://incomestatements.info
Category: Stock Reports